ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RMD / earnings
DXCM (76) MDLN (44) WST (81) BDX (67) ⌘ Pro Terminal →

ResMed Inc. (RMD) Next Earnings Date & Expected ±5.2% Move

$229.94 -9.05% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $226.75

ResMed Inc. (RMD) earns a Roarable Rating of A (Strong Buy) with 86/100 RQD Confidence. High-quality cash engine (59% profit margin, 23% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate) →
ROARABLE A • STRONG BUY Cap $35.56B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, ResMed Inc. (NYSE: RMD) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $229.94 (-9.05% 1D, market cap $35.56B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RMD ranks #3 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RMD compare to DXCM and MDLN in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), RMD carries a Roarable A (86/100 RQD), trailing P/E of 25.4x, gross margin of 59.4%, and ROIC of 22.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RMD?
▼

Per RMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000943819), ResMed Inc. generated $5.15B in revenue (+9.8% YoY), $1.40B in net income, and $1.66B in free cash flow against $8.50B in total assets and $982.1M in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $226.74 (-1.39%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 32.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSTRONG BUY • A
025507510086
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A · Rk A-
Cash (19)Whales (17)SEC (18)Macro (15)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+12.6% Base Target
$306 Bull$259 Base$189 Bear
📬 FREE RMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMD)Realized 20D OHLCV Swing Band: ±5.2%
Deterministic 5-Pillar Attribution (86/100 Composite)
🔍 WHY RMD SCORES 86/100 (A) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 32.3% FCF Margin ($1.66B FCF) & 59.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (21% of score)

Altman Z-Score 12.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit15/20 pts (-5 pt drag)

Macro rate sensitivity & RSI-14 (60.1) create a -5 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
94
Grade A+$235.04+4.5% Next Q
Q2 (-2Q)
91
Grade A+$245.50+2.2% Next Q
Q3 (-1Q)
89
Grade A$250.80-8.3% Next Q
Current
86
Grade A$229.94+9.2% Hist 90D α
Trajectory: A+ (94) → A (86)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 86/100 (A) score, RMD faces multiple-compression risk if 25.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 56.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($232.63) or 200D SMA ($224.82) invalidates the momentum regime and cuts Target Base ($258.91) toward Bear Floor ($188.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RMD Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 86%NO 14%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 28, 2026 (~55 DAYS)

Historical OHLCV Volatility ±5.2% Swing Band

±$11.96 Expected Swing
$217.98 (-5.2%)Spot $229.94$241.90 (+5.2%)
MODEL EARNINGS SETUP GAUGE

RMD Quantitative Pre-Earnings Setup: 86/100

Trailing EPS: $9.96 • YoY Revenue Growth: 9.8%

Model Bullish Setup (86/100)Model Risk Weight (14/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-06-30$5.15B$1.40B$1.66B59.4%
FY 20242024-06-30$4.69B$1.02B$1.30B56.7%
FY 20232023-06-30$4.22B$898.0M$503.3M59.4%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating RMD & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on RMD
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.79%🛡️ HOLDING TREND SUPPORT
2026-11-02O $250.2H $252.8L $229.9C $229.9VOL 1.45M
RES: $258.1SUP: $229.4SMA50: $232.6SMA200: $224.8
$260.8$239.0$217.2$195.3$173.5RES $258.1SUP $229.4$229.92026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RMD Butterfly Map → + Track RMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
19.1%/yr Implied 5Y Growth

vs. +9.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
LLY → RMD Analyst Hypothesis
FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity introduces the first pharmacologic disease-modifying competitor to ResMed CPAP devices.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMD)

Health Care Rank #3 of 1016 ⚔️ DXCM vs RMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RMD vs. DXCM, MDLN, WST, BDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ResMed Inc. (RMD) ranks #3 by composite RQD confidence (86/100, grade A) and #50 by equity capitalization ($35.56B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently leads its immediate peer cohort in composite quantitative strength at 86/100 (A).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RMD ACTIVE
ResMed Inc.
A 86/100 25.4x 59.4% 22.9% -9.05% $35.56B Benchmark Subject
DXCM
DexCom Inc.
B+ 76/100 36.1x 60.1% 21.6% +2.95% $30.16B /dxcm-vs-rmd →
MDLN
Medline Inc.
D 44/100 — — 8.2% +0.38% $42.07B /mdln-vs-rmd →
WST
West Pharmaceutical Services Inc.
A- 81/100 59.4x 35.9% 17.9% -0.97% $29.32B /wst-vs-rmd →
BDX
Becton Dickinson and Company
C+ 67/100 32.2x 45.4% 4.9% -0.23% $54.03B /bdx-vs-rmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000943819

In its most recent audited fiscal period (FY2025, filed 2025-06-30), ResMed Inc. (RMD) reported GAAP revenue of $5.15B (+9.8% vs. FY2024 revenue of $4.69B , and +21.9% cumulative change since FY2023) , GAAP net income of $1.40B, operating cash flow of $1.75B, and free cash flow of $1.66B (+27.6% YoY). On the balance sheet, RMD closed FY2025 with $8.50B in total assets against $982.1M in total debt (Altman Z-Score: 12.49, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $5.15B $1.40B $1.75B $1.66B $8.50B $982.1M
FY2024 (FY) 2024-06-30 $4.69B $1.02B $1.40B $1.30B $7.14B $849.7M
FY2023 (FY) 2023-06-30 $4.22B $898.0M $693.3M $503.3M $19.56B $4.58B

3. RMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, ResMed Inc. (NYSE: RMD) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $229.94 (-9.05% 1D, market cap $35.56B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RMD ranks #3 in composite RQD confidence.

How does RMD compare to DXCM and MDLN in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), RMD carries a Roarable A (86/100 RQD), trailing P/E of 25.4x, gross margin of 59.4%, and ROIC of 22.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RMD?

Per RMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000943819), ResMed Inc. generated $5.15B in revenue (+9.8% YoY), $1.40B in net income, and $1.66B in free cash flow against $8.50B in total assets and $982.1M in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RMD last traded at $229.94 (-9.05% on volume of 3,470,546 shares), positioning the stock -1.16% below its 50-day simple moving average ($232.63) and +2.28% above its 200-day simple moving average ($224.82). Across its 52-week range of $180.27 to $277.67, RMD sits at the 51.0% percentile with a 14-day RSI of 60.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.2% ($217.98 to $241.90).

RMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is RMD's next earnings date?

Based on SEC filing cadence, ResMed Inc. (RMD)'s next quarterly reporting window is estimated around Dec 28, 2026.

How much is RMD stock expected to move on earnings?

Volatility modeling currently projects a ±5.2% event move for RMD, spanning a range between $217.98 and $241.9.

Direct Sub-Reports: RMD RQD Cockpit RMD 12M Forecast RMD Earnings & Move RMD Dividends & DRIP RMD Insiders & 13F RMD Whale Options RMD Profit Sankey RMD News & Why
ROARABLE RATING BRIEF • RQD 86/100 (A) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RMD — ResMed Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 86, graded A, with the verdict "Roarable Strong Buy — Excellent Cash & Whale Support." Per the Roarable RQD rating, the five pillars score as follows: Fundamental Cash Engine 19/20 (ROIC 22.9%; FCF yield 4.67%), Whale 13F Flow 17/20 (institutional accumulation and options positioning), Insider Conviction 17/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 15/20 (beta 0.93; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 12.49; Piotroski F 9/9; Debt/Equity 0.15). For a prospective investor, the strongest support comes from cash generation and balance-sheet quality, which the rating treats as the highest-weighted evidence. The lowest-scoring pillar is macro regime fit, which indicates the stock's sensitivity to sector and market conditions is less favorable than its internal fundamentals. Valuation is a tradeoff: per the Snapshot data, the stock trades at 25.4x trailing earnings and 23.6x forward earnings, so the rating's cash-quality support must be weighed against a multiple that is not low. The rating is a structured summary of the source data and does not constitute personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$252.83$35.56B25.423.619.99.960.87%0.93$180.27 - $277.6722.9%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$5146.3M$1685.4M$1401.0MN/A$1661.7M$1417.1M$982.1M
FY 2024$4685.3M$1319.9M$1021.0MN/A$1301.8M$521.9M$849.7M
FY 2023$4223.0M$1131.9M$898.0MN/A$503.3MN/A$4576.3M

Per the market data, gross margin is 59.4%, operating margin 32.7%, and net margin 27.2%, with ROIC of 22.9%. Per the Roarable RQD rating, the Altman Z-Score is 12.49 and the Piotroski F-Score is 9/9, with Debt/Equity of 0.15. Revenue and net income rose across the three reported periods, and FY 2025 free cash flow was $1661.7M. The FY 2023 debt figure ($4576.3M) is markedly higher than the FY 2024 and FY 2025 figures and is not explained in the source data.

Open Questions

  • What is the company's revenue split by product line and customer segment, and how much is device versus mask re-supply?
  • What is the undisclosed exposure estimate cited in the 10-K for GLP-1 substitution, and what is the observed OSA script trend?
  • Why does FY 2023 debt ($4576.3M) differ so sharply from FY 2024 and FY 2025, and what does the reported cash balance look like for FY 2023?
  • What drove the recent share-price move reported in the news feed, given that article bodies are not provided?
  • What are the analyst consensus, price targets, and recent insider or 13F transactions that underpin the whale and insider pillar scores?

RMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ResMed Inc. (RMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RMD Bull vs. Bear Conversation Board — What's Your Call at $229.94?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $298.34 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RMD (A • RQD 86/100) a Buy at $252.83?

Welcome to the RMD (ResMed Inc.) Roar Pit. Current RQD Composite is 86/100 (Roarable Strong Buy — Excellent Cash & Whale Support) in Medical/Dental Instruments. Bulls point to capital efficiency (22.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $212.38 (-16.0%)
Spot @ $252.83

Pump the brakes on RMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RMD, but look at what you are paying: 25.4x trailing P/E with 59.4% gross margins. Unless ResMed Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $288.23 (+14.0%)
Spot @ $252.83

RMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $252.83 (52-wk range $180.27 - $277.67), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%